Chimerix Inc (CMRX)

HEALTH CARE: HEALTH CARE SUPPLIES
SIC: PHARMACEUTICAL PREPARATIONS

2505 MERIDIAN PARKWAY, SUITE 100 DURHAM, NC 27713

Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox.

Data based on most recent fiscal year report
Market Cap233.294 Million Shares Outstanding47.13 Million Avg Volume457.611 Thousand
1-Yr BETA vs S&P TR0.964 Current Ratio11.86 Quick Ratio11.86
View SEC Filings from CMRX instead.

View recent insider trading info

Funds Holding CMRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CMRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

30.7 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

NICHOLS GARRETT CHIEF MEDICAL OFFICER

  • Officer
271,421 2020-01-07 6

MACHADO PATRICK

  • Director
0 2020-01-01 1

LEONARD JOHN M.

  • Director
8,252 2019-12-20 0

MARIO ERNEST

0 2019-11-20 0

MIDDLETON FRED A

  • Director
3,458,923 2019-11-11 3

MEYER ROBERT J.

  • Director
10,000 2019-11-06 2

ANDRIOLE MICHAEL T. CHIEF BUSINESS OFFICER

  • Officer
100,000 2019-11-06 3

JAKEMAN DAVID PRINCIPAL ACCOUNTING OFFICER

  • Officer
76,006 2019-09-26 3

DALY JAMES M

  • Director
0 2019-09-09 1

CANTEX PHARMACEUTICALS, INC.

  • 10% Owner
0 2019-07-29 2

RENAUD RONALD C JR

  • Director
0 2019-06-20 1

DEMSKI MARTHA J

  • Director
0 2019-06-20 2

GILLISS CATHERINE

  • Director
0 2019-06-20 1

GREISSING ED

  • Director
0 2019-06-20 1

TROST TIMOTHY W. SVP, CFO & SECRETARY

  • Officer
217,088 2019-05-22 4

SHERMAN MICHAEL A. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
30,000 2019-05-20 3

ALRUTZ MICHAEL ALBERT PRINCIPAL EXECUTIVE OFFICER

  • Officer
156,645 2019-02-05 2

BERREY M MICHELLE PRESIDENT AND CEO

  • Officer
  • Director
0 2019-01-23 1

RICHARDSON LINDA M CHIEF COMMERCIAL OFFICER

  • Officer
54,161 2018-05-14 0

RICCIARDI LISA CHIEF OPERATING OFFICER

  • Officer
  • Director
0 2017-11-06 0

NIEDEL JAMES

  • Director
0 2017-06-28 0

ROGERS MICHAEL D. CHIEF DEVELOPMENT OFFICER

  • Officer
0 2016-01-08 0

WOLLAEGER TIMOTHY

  • Director
0 2015-06-22 0

SANDERLING VENTURE PARTNERS V, LP

  • 10% Owner
3,311,400 2014-09-12 0

SANDERLING VENTURE PARTNERS VI CO INVESTMENT FUND LP

  • 10% Owner
697,346 2014-09-05 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

NICHOLS GARRETT - Officer CHIEF MEDICAL OFFICER

2020-01-07 S 30,680 $2.15 d 271,421 271,421.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments